Caspase 8 initiates apoptosis downstream of TNF death receptors by undergoing autocleavage and processing the executioner caspase 3 (ref. 1). However, the dominant function of caspase 8 is to transmit a pro-survival signal that suppresses programmed necrosis (or necroptosis) mediated by RIPK1 and RIPK3 (refs 2-6) during embryogenesis and haematopoiesis 7-9 . Suppression of necrotic cell death by caspase 8 requires its catalytic activity but not the autocleavage essential for apoptosis 10 ; however, the key substrate processed by caspase 8 to block necrosis has been elusive. A key substrate must meet three criteria: it must be essential for programmed necrosis; it must be cleaved by caspase 8 in situations where caspase 8 is blocking necrosis; and mutation of the caspase 8 processing site on the substrate should convert a pro-survival response to necrotic death without the need for caspase 8 inhibition. We now identify CYLD as a substrate for caspase 8 that satisfies these criteria. Following TNF stimulation, caspase 8 cleaves CYLD to generate a survival signal. In contrast, loss of caspase 8 prevented CYLD degradation, resulting in necrotic death. A CYLD substitution mutation at Asp 215 that cannot be cleaved by caspase 8 switches cell survival to necrotic cell death in response to TNF.
for necrotic cell death (the first criterion in the first paragraph). Immunoprecipitation of FADD from CYLD-expressing and control Cyld −/− MEFs treated with TNF in the presence of zVAD-fmk revealed that recruitment of RIPK1 to the FADD necrosome is strictly dependent on CYLD (Fig. 1c ). To our surprise, immunoblotting to detect the ectopic CYLD in the reconstituted MEFs revealed that CYLD protein was rapidly lost following TNF stimulation (Fig. 1d ). In contrast, protein levels of RIPK1 and RIPK3 were relatively unchanged, indicating that removal of CYLD may regulate necrosis.
To examine whether degradation of CYLD observed in TNFstimulated MEFs was due to proteolytic cleavage, FLAG-CYLD was immunoprecipitated from the reconstituted Cyld −/− MEFs and blotted with the same antibody. A FLAG-tagged product from CYLD with a relative molecular mass of approximately 25,000 (M r 25K; CYLDp25) was detected following TNF stimulation ( Fig. 2a ), indicating that CYLD may undergoe cleavage. Furthermore, the M r 25K cleavage product from endogenous CYLD was similarly detected in untransfected wild-type MEFs (Fig. 2b ). We reasoned that the CYLD protein might be regulated by active caspase 8, particularly as computational analysis also indicated a relationship between caspase 8 and CYLD gene expression levels ( Supplementary Fig. S1 ), especially in lymphoid cells. Consistent with this hypothesis, the caspase 8 inhibitor IETD-fmk decreased the level of the CYLDp25 fragment. Co-transfection of HEK293 cells revealed that overexpression of wild-type caspase 8, but not the catalytically inactive mutant caspase-8 C360S , causes degradation of the CYLD protein ( Fig. 2c ). Interaction between transfected CYLD and caspase 8 by co-immunoprecipitation was observed only when the activity of caspase 8 was blocked by the pan-caspase inhibitor zVAD-fmk, or by mutation of the caspase 8 active site, indicating that CYLD is a substrate for proteolytic cleavage by caspase 8 (Fig. 2d ). To provide genetic evidence that caspase 8 is cleaving CYLD, FLAG-CYLD was stably expressed in Casp8 +/+ and Casp8 −/− MEFs and the cells were stimulated with TNF. The p25 fragment was not detected in 10 0 10 1 10 2 10 3 10 4 10 1 10 2 10 3 10 4 10 1 10 2 10 3 10 4 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 1 10 2 10 3 10 4 10 1 10 2 10 3 10 4 10 1 10 2 10 3 10 4 10 0 the Casp8 −/− MEFs ( Fig. 2e ), indicating that CYLDp25 is a product of the proteolytic cleavage of CYLD by caspase 8, under conditions where active caspase 8 suppresses necrosis 7, 12 (the second criterion in the first paragraph). In the MEF model, caspase 8 generates a survival signal. As caspase 8 is also known to initiate apoptosis, which antagonizes programmed necrosis, we examined whether CYLD is similarly cleaved by caspase 8 during apoptosis in the human Jurkat T-cell model. Levels of endogenous CYLD were decreased following TNF stimulation of SMAC-mimetic 13 -treated parental Jurkat T cells (clone A3) but not in the caspase-8-deficient mutant clone I9.2 ( Supplementary Fig. S2a ). Similarly, endogenous CYLD was cleaved to generate CYLDp25 when caspase 8 was activated following TNF stimulation of NEMO-deficient Jurkat T cells 14 (clone 8321; Supplementary Fig. S2c ). CYLD was not cleaved in caspase-8-deficient Jurkat T cells treated with TNF and SMAC mimetic ( Supplementary Fig. S2a,d) , which failed to undergo apoptosis but instead died by programmed necrosis 5 ( Supplementary   Fig. S2b ). As for the MEF model, a correlation between the stabilization of CYLD and necrosis is also observed in the Jurkat T-cell model. Finally, we examined CYLD cleavage in a third model using murine L929 cells. Cleavage of endogenous CYLD ( Supplementary Fig. S3a ) or transfected FLAG-tagged CYLD ( Supplementary Fig. S3b ) could be detected in TNF-treated L929 cells in a caspase-dependent manner. When caspase 8 activity was inhibited, L929 cells died by necrosis, which was blocked by knockdown of either CYLD or RIPK3 ( Supplementary  Fig. S3c ). Processing of CYLD to CYLDp25 was also observed in SMAC-mimetic-and TNF-treated MCF7 human breast cancer cells ( Supplementary Fig. S4a ), which are deficient in caspase 3 (ref. 15 ), indicating that caspase 3 is not required for CYLD cleavage. Therefore, CYLD cleavage by caspase 8 is observed whether it is generating a survival or an apoptotic death signal, and CYLD stabilization coincided with cells undergoing necrosis. To provide further corroboration that caspase 8 activity was required for CYLD cleavage, we stably expressed CrmA, a viral inhibitor of caspase 8 and a known trigger of programmed necrosis 2,4 , in FLAG-CYLD-expressing MEFs. CrmA prevented processing of CYLD to CYLDp25 ( Supplementary Fig. S4b ), whereas an aspartic acid to alanine mutation that abrogates the ability of CrmA to inhibit caspase 8 (CrmA D303A ) was unable to prevent cleavage of CYLD. Similarly, expression of wild-type CrmA predisposed MEFs to programmed necrosis following TNF treatment, whereas expression of mutant CrmA did not ( Supplementary Fig. S4c ). Therefore, the genetic data from MEFs and Jurkat T cells indicate that the cleavage of CYLD following TNF treatment requires caspase 8. The data with the pharmacological and viral inhibitors of caspase 8 activity indicate that proteolytically active caspase 8 is required for processing of CYLD. To determine whether caspase 8 could directly cleave CYLD, affinity-purified FLAG-tagged CYLD protein was incubated with recombinant caspase 8. Purified CYLD protein was processed by recombinant caspase 8 to generate the amino-terminal CYLDp25 fragment ( Fig. 2f ). Therefore, caspase 8 directly cleaves CYLD. Amino-acid sequences of CYLD from several species were aligned to identify a conserved caspase 8 cleavage site motif (LxxD) that would produce an N-terminal M r 25 (K) fragment ( Fig. 3a ). Two potential motifs were identified and mutation of Asp 215 was sufficient to prevent proteolysis of CYLD by caspase 8. Following co-expression in HEK293 cells, CYLD D215A was more resistant to degradation by caspase 8 (Fig. 3b ) even though both wild-type CYLD and CYLD D215A co-precipitated with caspase 8 (Fig. 3c) to the same extent. The D215A mutation abrogated the appearance of CYLDp25 in TNF-stimulated reconstituted Cyld −/− MEFs ( In both the MEF and Jurkat T-cell models, there was a strict correlation between necrosis and stabilization of CYLD. CYLD was rapidly lost in TNF-treated caspase-8-sufficient Jurkat T cells dying by apoptosis but remained unchanged in the caspase-8-deficient cells dying by necrosis ( Supplementary Fig. S2a ). Cell death in caspase-8-deficient Jurkat T cells was blocked by necrostatin-1 (refs 2,16), confirming that caspase 8 represses programmed necrosis ( Supplementary Fig. S2b ). Similarly, blocking CYLD cleavage in MEFs with caspase inhibitors correlated with entry into necrotic death (Figs 1b and 2b). Whereas marked downregulation of CYLD was observed in TNF-treated cells, no detectable change occurred for RIPK1 and RIPK3 in either model ( Fig. 1d and Supplementary  Fig. S2a ). Therefore, we reasoned that CYLD is the key substrate cleaved by caspase 8 to prevent necrosis. To test this hypothesis, Cyld −/− MEFs stably reconstituted with wild-type CYLD or CYLD D215A were treated with TNF. CYLD D215A -expressing MEFs quickly died by necrosis, without the need for a caspase inhibitor (Fig. 4a ). In contrast, significant numbers of MEFs expressing wild-type CYLD underwent necrosis only if treated with TNF in the presence of IETD-fmk ( Fig. 4a ) or zVAD-fmk ( Fig. 4b ). Cell death initiated by TNF in Cyld −/− MEFs expressing CYLD D215A was blocked by the RIPK1 inhibitor necrostatin-1 (ref. 17 ; Fig. 4a , compare the two middle panels in the bottom row), or by specific knockdown of Ripk1 or Ripk3 (Fig. 4c ), demonstrating that RIPK1 and RIPK3 are downstream of CYLD. Neither RIPK1 nor RIPK3 was required for the processing of CYLD to CYLDp25 in MEFs ( Supplementary Fig. S4d ), indicating that caspase 8 inactivation of CYLD occurs upstream of these necrosome components.
Recruitment of RIPK1 to the necrosome is strictly dependent on CYLD ( Fig. 1c ) and caspase 8 removal of CYLD would be expected to prevent the recruitment of RIPK1. Therefore, stabilizing CYLD by mutating the caspase 8 cleavage site at Asp 215 is sufficient to permit TNF-induced necrosis even in the presence of caspase 8 (the third criterion in the first paragraph). CYLD is a deubiquitylase that removes K63-polyubiquitin chains from RIP1 (ref. 18); these ubiquitin chains are required for recruitment of signalling molecules such as NEMO (refs 19,20) that prevent RIPK1 from functioning as a pro-death molecule 21, 22 , in part by preventing RIPK1 from associating with downstream death signalling molecules and in part by mediating activation of pro-survival NFκB. Consistent with an inhibitory role for CYLD during IKK activation, Cyld −/− MEFs exhibit faster kinetics of IκBα phosphorylation when compared with Cyld −/− MEFs reconstituted with wild-type CYLD ( Supplementary  Fig. S5a ). However, the kinetics of IκBα phosphorylation seems to be fairly similar between the Cyld −/− cells reconstituted with wild-type CYLD or CYLD D215A , with the D215A cells exhibiting a modest decrease in IκBα phosphorylation at 60 min. In a control experiment, mutation of Asp 215 did not affect the ability of CYLD to bind NEMO in HEK293 cells ( Supplementary Fig. S5b ). We confirmed that the level of wild-type CYLD was decreased following TNF stimulation, whereas the CYLD D215A mutant was not ( Supplementary Fig. S6a ), coincident with survival in the former and necrotic cell death in the latter. Thus, whereas the CYLD D215A mutation had a minimal effect on NF-κB signalling, it had a striking effect on necrosis, indicating that CYLD deubiquitylation of downstream molecules such as RIPK1 may control entry into this death pathway. To test this hypothesis, we first examined the fate of the carboxy-terminal p82 fragment containing the deubiquitylase domain resulting from the cleavage. In experiments up to this point, this C-terminal fragment was not detectable, indicating that it may be unstable. Sequence analysis of CYLD indicated a PEST motif from amino acids 397 to 415. Addition of the proteasome inhibitor MG132 to TNF-stimulated MCF7 cells (Fig. 5a ) or MEFs ( Supplementary Fig. S6b ) led to the stabilization of the p82 fragment. Therefore, when TNF is promoting survival, caspase 8 cleaves CYLD to remove the deubiquitylase domain, which is likely to affect RIPK1 ubiquitylation and its interaction with signalling partners. We examined this by immunoprecipitating the pro-survival NEMO complex from TNF-treated MEFs expressing wildtype CYLD and CYLD D215A because NEMO binds ubiquitylated RIPK1 (refs 19,20) . Therefore, the amount of RIPK1 in the NEMO complex can be regarded as an indirect measure of RIPK1 ubiquitylation. Furthermore, the NEMO-RIPK1 complex has been proposed to be a survival complex that functions by preventing RIPK1 from interacting with downstream death signalling molecules [22] [23] [24] . More RIPK1 protein co-precipitated with NEMO from MEFs expressing wild-type CYLD than from MEFs expressing CYLD D215A , indicating that the level of RIPK1 ubiquitylation may be decreased in the D215A cells ( Fig. 5b) . Interestingly, the level of ubiquitylated proteins in the NEMO complex was decreased in CYLD D215A MEFs at both steady state and following TNF stimulation, consistent with the idea that CYLD stabilization resulted in enhanced deubiquitylase activity (Fig. 5b) . The ubiquitylation level of RIPK1 was directly examined by RIPK1 immunoprecipitation followed by blotting with anti-ubiquitin. RIPK1 isolated from the CYLD D215A MEFs exhibited lower levels of ubiquitylation after TNF stimulation, which is most discernible at 2 and 3 h ( Fig. 5c ), indicating that stabilization of the CYLD protein may lead to an accelerated rate of deubiquitylation of RIPK1 concurrent with a decreased level of interaction of RIPK1 with the pro-survival NEMO protein. Disruption of the interaction of RIPK1 with NEMO would be predicted to lead to increased association of RIPK1 with the downstream necrotic death apparatus. Indeed, more RIPK1 was recruited to the necrosome complex after 90 min of TNF treatment of CYLD D215A -expressing MEFs (Fig. 5d ). Therefore, removal of wild-type CYLD by caspase 8 prolongs the ubiquitylation state of RIPK1 and maintains RIPK1 in a pro-survival complex with NEMO. In contrast, the resistance of CYLD D215A to proteolytic cleavage by caspase 8 resulted in a lower level of ubiquitylation of RIPK1 ( Fig. 5 ), which enhanced RIPK1 interaction with the necrosome to initiate death (Fig. 4) . These observations demonstrate that caspase 8 cleavage of CYLD functions as a pro-survival event by preventing CYLD from deubiquitylating RIPK1.
We provide evidence that CYLD is cleaved by caspase 8 to promote survival. Significantly, the cleavage fragment containing the deubiquitylase domain is unstable and undergoes degradation by the proteasome. The CYLD level diminished in a time-dependent manner after TNF stimulation, indicating that CYLD may be continuously recruited to and degraded by the caspase 8 signalling complex to maintain the suppression of necrosis. Caspase-8-dependent CYLD degradation is also observed in cells undergoing apoptosis, which antagonizes necrosis. Therefore, proteolytic degradation of CYLD may serve to disable the necrosis machinery in multiple settings. More significantly, mutation of the cleavage site on CYLD drives MEFs into necrotic cell death with no requirement for caspase inhibition. Cleavage of CYLD by caspase 8 is both necessary and sufficient for caspase 8 to repress programmed necrosis, indicating that processing of CYLD is the critical determinant of cell survival versus death by necrosis in MEFs. Processing of CYLD by caspase 8 does not require RIPK1 or RIPK3, which indicates that this cleavage event may occur early after TNFR1 ligation to prevent recruitment of RIPK1 to the necrosome. When the removal of CYLD by caspase 8 is prevented by mutation of Asp 215, we observe an accelerated rate of deubiquitylation of RIPK1 and the dismantling of the pro-survival RIPK1 and NEMO complex, with the concomitant formation of the RIPK1 and FADD necrosome complex. As CYLD is a tumour suppressor 25 and can be removed by caspase 8, this study should motivate a re-examination of the controversial role of caspase 8 in tumorigenesis. CYLD is a known regulator of other non-apoptotic functions attributed to active caspase 8, such as proliferation, cell migration and metastasis 26 ; therefore, processing of CYLD by caspase 8 is likely to have important biological functions that extend beyond the repression of programmed necrosis. propidium iodide, necrostatin-1, MG132 and zVAD-fmk (Calbiochem), zVADfmk and IETD-fmk (Imgenex) and recombinant human TNF (PeproTech) were purchased from the indicated sources. Antibodies against caspase 3, caspase 8 and phospho-IκBα (Cell Signaling), IκBα (Imgenex), CYLD C terminus, FADD and ubiquitin (Santa Cruz), CYLD N terminus (Invitrogen), mouse RIPK3 (ProScience), HA and myc (Roche), RIPK1 (Pharmingen), actin and FLAG antibody and beads (Sigma) were purchased from the indicated sources. The human RIPK3 antibody and SMAC mimetics 5 were provided by X. Wang (UT Southwestern, Dallas, Texas, USA). All western blots were probed with primary antibodies at 1 µg ml −1 , except human RIPK3 (rabbit serum was diluted 1:2,000); horseradish-peroxidaseconjugated secondary antibodies (Jackson Laboratories) were used at the following concentrations: anti-mouse 0.08 µg ml −1 , anti-rabbit 0.026 µg ml −1 .
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Cell lines. The HEK293 derivative cell line 293EBNA was obtained from Invitrogen.
Wild-type (clone A3) and caspase-8-deficient (clone I9.2) Jurkat cell lines were obtained from ATCC. Casp8 +/+ and Casp8 −/− MEFs have been described previously 7 . Cyld −/− MEFs have been described previously 25 .
Cell viability assays. Cells undergoing programmed necrosis expose phosphatidyl serine on the outer face of the plasma membrane [27] [28] [29] [30] ; therefore, Annnexin V staining is a valid method to detect necrotic cells. For Annexin V staining of fibroblasts, subconfluent MEFs or L929 cells were counted and plated to give approximately 30-50% cell density. At 24 h after treatment with TNF, detached dead cells were removed with the tissue culture supernatant. The remaining adherent cells were briefly trypsinized and combined with the detached cells. MEFs were washed once with Annexin V binding buffer (10 mM HEPES, 140 mM NaCl and 2.5 mM CaCl 2 , at pH 7.5), resuspended in 100 µl binding buffer and incubated with 1 mg l −1 Annexin V-PE for 5 min before immediate analysis on a Becton Dickinson FACScan flow cytometer or an Accuri C6 flow cytometer. For Annexin V staining of Jurkat T cells, approximately 5 × 10 5 T cells per sample were stimulated as described and then washed once with Annexin V binding buffer, resuspended in binding buffer and incubated with 1 mg l −1 Annexin V-PE for 5 min before immediate analysis on a Becton Dickinson FACScan flow cytometer. Flow cytometry data were analysed using CellQuest (Becton Dickinson), FlowJo or CFlow (Accuri) software. Samples were gated to exclude cellular debris according to the forward and side scatter. Cells were typically treated with between 10 and 100 pg ml −1 (MEFs) and 10 ng ml −1 (Jurkat T cells) human TNF to induce programmed necrosis. Cells were pre-incubated with 10 µM zVAD-fmk, 50 µM IETD-fmk, 30 µM necrostatin-1 or 100 nM SMAC mimetic, as indicated.
Bioinformatics analysis. Analysis of gene expression across 79 tissues was carried out as described previously 31 . Briefly, microarray data files were obtained from the Novartis GNF human expression atlas version 2 resource 32 , and expression values of probe sets from the HG-U133A (Affymetrix) platform and the GNF1H custom chip were analysed. The data set was normalized by using global median scaling and we filtered the data by excluding from the analysis probe sets with 100% 'absent' calls (MAS 5.0 algorithm) across all 79 tissues. Z -score transformation was applied to each probe set across all arrays before generating 'heatmaps' for visualization using TreeView 33 .
Immunoprecipitation. For immunoprecipitation of FLAG-tagged proteins, approximately 10 × 10 6 HEK293 cells or 3 × 10 6 MEFs were lysed in 1,500 µl Triton X-100 lysis buffer on ice for 20 min as previously described 31 . Samples were centrifuged at 20,000g for 10 min and the supernatants were incubated with M2 FLAG beads (Sigma) for 2 h to overnight. Beads were washed 5 times with 1,000 µl Triton X-100 lysis buffer (250 mM NaCl) and once with peptide elution buffer. Immunoprecipitated proteins were eluted in 300 µg ml −1 3×FLAG peptide (Sigma) in peptide elution buffer for 1 h on ice before SDS-PAGE. Cells were treated with human TNF for 5 h, in the presence of 100 nM SMAC mimetic when appropriate, to induce cleavage of FLAG-CYLD: 10 ng ml −1 human TNF was used for Cyld −/− MEFs, 50 ng ml −1 human TNF for Casp8 −/− MEFs, 50 ng ml −1 human TNF + SMAC mimetic for Jurkat T cells and MCF7 cells. To isolate NEMO and FADD complexes, approximately 30 × 10 6 MEFs were lysed in NP-40 lysis buffer (0.2% NP-40, 20 mM Tris, 150 mM NaCl and 10% glycerol, at pH 7.5) for 30 min on ice. Samples were centrifuged at 20,000g for 10 min and the supernatants were incubated with NEMO or FADD-specific antibody (Santa Cruz) overnight. Protein A/G beads (Santa Cruz) were added for a further 2 h at 4 • C and the beads were washed five times with lysis buffer. NEMO-and FADD-associated proteins were eluted by incubating the beads in SDS-PAGE loading buffer at 70 • C for 20 min. RIPK1 immunoprecipitations were carried out similarly with anti-RIPK1 but the beads were washed five times with RIPA buffer (50 mM Tris, 500 mM NaCl, 1% Triton X-100, 1% Na deoxycholate and 0.1% SDS, at pH 7.4) before SDS-PAGE.
Recombinant caspase 8 cleavage assay. FLAG-tagged wild-type CYLD and CYLD D215A were purified from reconstituted Cyld −/− MEFs by FLAG immunoprecipitation as described above, except the beads were washed with buffer containing 500 mM NaCl. FLAG-tagged proteins were eluted with FLAG peptide and then combined with 3U of recombinant caspase 8 (Millipore) in a reaction buffer (50 mM HEPES, 50 mM NaCl, 0.1% CHAPS, 10 mM EDTA, 5% glycerol and 10 mM dithiothreitol). Samples were incubated at 37 • C for 2 h and the entire reaction was subject to SDS-PAGE followed by immunoblotting with anti-FLAG and anti-caspase 8.
Whole-cell lysates. Cells were washed once with PBS and lysed with 0.5% SDS.
Lysates were vortexed for 1 min, boiled for 5 min and vortexed again to shear genomic DNA. Protein concentration was determined by BCA assay (Pierce) and between 25 and 75 µg of protein was typically subject to SDS-PAGE.
RNA interference. For transient knockdown, cells were plated in media with no antibiotics and once attached were transfected with siRNA duplexes targeting Casp8, Cyld, Ripk1 and Ripk3 or with a non-silencing control. MEFs were transfected on two consecutive days with 150 nM non-targeting RNA duplexes or duplexes targeting Ripk1, Ripk3 or Casp8 using the DharmaFECT1 reagent. At 48 h after the second transfection, cells were re-plated and used in experiments the following day. siRNA duplex oligonucleotides were obtained from Dharmacon: On-targetplus mouse Casp8-1 (5 -GUGAAUGGAACCUGGUAUA-3 ), On-targetplus mouse Casp8-2 (5 -GUCACGGACUUCAGACAAA-3 ), On-targetplus smartpool mouse Ripk1 (5 -CAACCGCGCUGAGUACAAU-3 , 5 -GAAGGCAUGUGCUACUUAC-3 , 5 -CCUCGUUGAUCGUGACUUU-3 , 5 -UCACCAAUGUUGCAGGAUA-3 ) and On-targetplus smartpool mouse Ripk3 (5 -ACACGGCACUCCUUGGUAU-3 , 5 -GGUAAAGCAUUAUCUGUCU-3 , 5 -CAAGUUCGGCCAAGUAUGA-3 , 5 -UCAAGAUCGUGAACUCGAA-3 ). For stable knockdown, L929 cells were transduced with pSUPERretro-puromycin encoding scrambled or Ripk3-targeting short hairpin RNAs as described previously 7 .
Plasmids. Constructs encoding FLAG-GFP, myc-CYLD, FLAG-CYLD wild type, FLAG-CYLD D215A , wild-type caspase-8-HA, caspase-8 C360S -HA, HA-CrmA wild type and HA-CrmA D303A were constructed using standard recombinant DNA techniques. Point mutations were generated with the QuikChangeXL site-directed mutagenesis kit (Stratagene). For transient expression, genes were cloned into the EF1α-driven PEAK8 or CMV-driven pcDNA3 vectors. For stable expression, genes were inserted into a MMLV-based retroviral vector upstream of an IRES-puromycin resistance cassette described previously 21, 31 . VSV-G-pseudotyped viruses were generated and infection was carried out as described previously 21 . NEMO-deficient Jurkat T cells (clone 8321) were stimulated with 10 ng/ml TNF for 5 hours in the presence of 50 µM IETD-fmk. SDS-soluble lysates were blotted with antibody that recognises the N-terminus of CYLD. The unprocessed CYLDp107 and the CYLDp25 cleavage product generated from endogenous CYLD are indicated. (d) CASPASE 8-sufficient and CASPASE 8-deficient Jurkat T cells stably expressing FLAG-CYLD-WT were treated with 100 nM SMAC mimetic for one hour and then stimulated with 50 ng/ml human TNF for a further three hours in the presence of vehicle or 50 µM IETD-fmk, as indicated. FLAG-tagged CYLD proteins were immunoprecipitated from triton-soluble lysates and immunoblotted with FLAG-specific antibody to detect unprocessed CYLD (p107) and the CYLD cleavage product (p25) generated by active CASPASE 8. (e) CASPASE 8-sufficient Jurkat T cells stably expressing FLAG-CYLD-WT or FLAG-CYLD-D215A were treated with 100 nM SMAC mimetic for one hour and then stimulated with 50 ng/ml human TNF for a further three hours in the presence of vehicle or 50 µM IETD-fmk, as indicated. FLAGtagged CYLD proteins were immunoprecipitated from triton-soluble lysates and immunoblotted with FLAG-specific antibody to detect unprocessed CYLD (p107) and the CYLD cleavage product (p25) generated by active CASPASE 8. Figure 2 
